KTTA
Pasithea Therapeutics Corp.NASDAQHealthcare$0.77+3.48%ClosedMarket Cap: $5.7M
As of 2026-04-06
Valuation
View DetailsP/E (TTM)
—
PEG
—
P/B
0.00
P/S
0.00
EV/EBITDA
2741.01
DCF Value
$7,845.11
FCF Yield
-26905.7%
Div Yield
0.0%
Margins & Returns
Gross Margin
0.0%
Operating Margin
0.0%
Net Margin
0.0%
ROE
-147.9%
ROA
-36.2%
ROIC
-37.7%
Financials
View All| Period | Revenue | Net Income | EPS |
|---|---|---|---|
| Q4 2025 | $0.00 | $-20.42B | $1.41 |
| FY 2025 | $0.00 | $-20.43B | $-2.91 |
| Q3 2025 | $0.00 | $-3.0M | $-0.41 |
| Q2 2025 | $0.00 | $-3.7M | $-0.66 |
Trading Activity
Insider Trades
View AllSTEINMAN LAWRENCEdirector
BuyMon Dec 01
Schneiderman Daniel Hofficer: Chief Financial Officer
SellMon Dec 01
Marques Tiagodirector, officer: Chief Executive Officer
BuyMon Dec 01
Dumesnil Simondirector
BuyMon Dec 01
Leahy Emerdirector
SellMon Dec 01
Company Info
Sector
Healthcare
Industry
—
Country
US
Exchange
NASDAQ
Beta
0.20
Pasithea Therapeutics Corp., a biotechnology company, engages in research and discovery of treatments for psychiatric and neurological disorders. It also intends to operate anti-depression clinics and provide business support services using trained pharmacists to administer intravenous infusions of ketamine. The company was incorporated in 2020 and is headquartered in Miami Beach, Florida.